Search results for "Nausea"

showing 10 items of 138 documents

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.

2019

Abstract Background Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has historically been associated with grade III pyrexia or photosensitivity depending on the combination used. The objective of this study was to fully describe adverse events from the COLUMBUS study evaluating the most recent BRAF/MEK inhibitor combination encorafenib+binimetinib. Patients and methods Patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma were randomised to receive encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, encorafenib 300 mg on…

Encorafenib0301 basic medicineOncologyMaleCancer ResearchSkin NeoplasmsBinimetinib; Encorafenib; Melanoma; Safety; Vemurafenib;MedizinBinimetinibchemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy Protocols1306 Cancer ResearchVemurafenibMelanomaFatigueeducation.field_of_studySulfonamidesMEK inhibitorMelanomaStandard treatmentIncidence10177 Dermatology ClinicBinimetinibNauseaMiddle AgedOncology030220 oncology & carcinogenesis2730 OncologyFemaleSafetyMitogen-Activated Protein Kinasesmedicine.drugProto-Oncogene Proteins B-rafmedicine.medical_specialtyVomitingPopulation610 Medicine & health03 medical and health sciencesInternal medicinemedicineHumanseducationAdverse effectProtein Kinase Inhibitorsbusiness.industrymedicine.diseaseDiscontinuation030104 developmental biologychemistryVemurafenibMutationBenzimidazolesCarbamatesbusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

A Prospective Open‐Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medicat…

2021

Upper gastrointestinal (GI) side effects are a main reason for discontinuing bisphosphonate treatment, an important therapeutic option for osteoporosis patients. Consequently, the development of novel formulations with improved tolerability is warranted. In this multicenter prospective, observational, postauthorization safety study conducted in Italy and Spain, postmenopausal women (PMW) with osteoporosis (naïve to bisphosphonates) were treated weekly with a buffered soluble alendronate 70 mg effervescent (ALN-EFF) tablet (Binosto®) and followed for 12 ± 3 months. Information was collected on adverse events (AEs), medication errors, persistence, and compliance using the Morisky-Green questi…

GASTROINTESTINAL ADVERSE EVENTSmedicine.medical_specialtyAgingNauseaEndocrinology Diabetes and MetabolismOsteoporosisDiseases of the musculoskeletal systemOSTEOPOROSISInternal medicineparasitic diseasesmedicineClinical endpointOrthopedics and Sports MedicineCumulative incidenceAdverse effectALENDRONATEOrthopedic surgerybusiness.industryalendronate; effervescent; gastrointestinal adverse events; osteoporosis; postmenopausal womenEvaluation of treatments and therapeutic interventionsEFFERVESCENTOriginal Articlesmedicine.diseaseConfidence intervalDiscontinuationTolerabilityPOSTMENOPAUSAL WOMENRC925-9356.1 PharmaceuticalsOsteoporosisOriginal ArticlePatient Safetymedicine.symptombusinessDigestive DiseasesRD701-811JBMR Plus
researchProduct

Pre-Emptive Treatment with Cidofovir for Cytomegalovirus Antigenemia in Autologous Bone Marrow Recipient and CLL Patients on Therapy with Alemtuzumab.

2006

Abstract Cytomegalovirus (CMV) is an important cause of morbidity and mortality in patients who have undergone severe immunosuppressive therapy. Ganciclovir continues to be the first choice for pre-emptive therapy, but it needs multiple intravenous daily administration for three weeks and may cause myelosuppression. Cidofovir is a non myelotoxic nucleotide analogue effective against CMV; its favourable pharmacokinetic profile allows a once-a-week dosing. We reviewed a database on 110 consecutive Autologous Stem Cell Transplant (ASCT) and that of 15 Chronic Lymphocytic Leukemia (CLL) patients treated with alemtuzumab. All patients were virologically monitored by quantification of pp65 antige…

Ganciclovirmedicine.medical_specialtyNauseaChronic lymphocytic leukemiaImmunologyCongenital cytomegalovirus infectionBiochemistryGastroenterologySettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundInternal medicinemedicineProteinuriabusiness.industryvirus diseasesCell BiologyHematologymedicine.diseaseSurgerychemistryVomitingCytomegalovirus pre-emptive treatment cidofovirAlemtuzumabmedicine.symptombusinessmedicine.drugCidofovirBlood
researchProduct

Role of Octreotide, Scopolamine Butylbromide, and Hydration in Symptom Control of Patients with Inoperable Bowel Obstruction and Nasogastric Tubes

2000

Bowel obstruction may be an inoperable complication in patients with end-stage cancer. Scopolamine butylbromide (SB) and octreotide (OCT) have been successfully used with the aim of reducing gastrointestinal (GI) secretions to avoid placement of a nasogastric tube (NGT); however, there have been no comparative studies concerning the efficacy of these drugs. Furthermore, there is little information about the role played by parenteral hydration in symptom control of these patients. In a prospective trial that involved all 17 inoperable bowel-obstructed patients presenting to our services with a decompressive NGT, patients were randomized to OCT 0.3 mg/day or SB 60 mg/day for 3 days through a …

Gastrointestinal agentPalliative carebusiness.industryNauseaOctreotideAbdominal distensionmedicine.diseaselaw.inventionBowel obstructionAnesthesiology and Pain MedicineRandomized controlled triallawAnesthesiaMedicineNeurology (clinical)medicine.symptombusinessProspective cohort studyGeneral Nursingmedicine.drugJournal of Pain and Symptom Management
researchProduct

A life put on pause: an exploration of the health-related quality of life issues relevant to adolescents and young adults with cancer

2018

Purpose: in recent years, the assessment of health-related quality of life (HRQoL) has been recognized as particularly informative to health care providers. For adolescents and young adults (AYAs), the impact of a cancer diagnosis and subsequent treatment is likely to be distinct from other age groups given the unique and complex physical and psychosocial challenges of this developmental phase. The objective of this study was to capture the HRQoL issues described by AYAs with cancer using thematic analysis.Methods: semi-structured interviews were carried out with 45 AYAs aged 14-25 years from 6 countries. Results: the most prevalent cancers presented were leukemia (n=12) and lymphoma (n=8).…

Gerontologybusiness.industryNauseaFamily lifehumanities03 medical and health sciencesAll institutes and research themes of the Radboud University Medical Center0302 clinical medicineQuality of life (healthcare)Oncology030220 oncology & carcinogenesisPediatrics Perinatology and Child HealthMedicineAnxiety030212 general & internal medicineYoung adultmedicine.symptomThematic analysisbusinessPsychosocialDepression (differential diagnoses)Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
researchProduct

Ovarian Hyperstimulation Syndrome as a Growing Diagnostic Problem in Emergency Department Settings: A Case Report.

2018

Abstract Background Ovarian hyperstimulation syndrome (OHSS) is a common complication of an in-vitro fertilization (IVF) procedure, which is usually clinically insignificant. However, without monitoring, it can progress into a life-threatening condition. With the increasing popularity of IVF technology, patients with OHSS may begin visiting emergency departments (EDs) more frequently. Case Report We report the case of a patient admitted to the ED presenting with severe abdominal pain, cough, and nausea. An ultrasound examination was inconclusive. Computer tomography revealed enlarged ovaries and fluid in the pleural cavities, around the liver and spleen, between the bowel loops, and in the …

InfertilityAdultAbdominal painmedicine.medical_specialtyNauseamedia_common.quotation_subjectOvarian hyperstimulation syndromeFertilityFertilization in Vitro03 medical and health sciencesOvarian Hyperstimulation Syndrome0302 clinical medicinemedicineHumansEmergency physicianIntensive care medicinemedia_common030219 obstetrics & reproductive medicinebusiness.industryNauseaEmergency departmentmedicine.diseaseAbdominal PainCoughIVFInfertilityEmergency MedicineFemalemedicine.symptomComplicationbusinessEmergency Service HospitalTomography X-Ray Computed030217 neurology & neurosurgeryThe Journal of emergency medicine
researchProduct

Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series

2019

Background. Vinflunine (VFL) is approved in Europe as second-line treatment of metastatic urothelial cancer after failure of platinum-containing therapy. We performed a systematic review and meta-analysis of real-world data (RWD) to assess utilization, efficacy and safety of VFL. \ud \ud Methods. We performed a MEDLINE search for the period of 1/1/2000-31/8/2017. Full-length articles providing post-marketing RWD on VFL in patients failing previous chemotherapy were eligible. Interventional clinical trials were excluded. \ud \ud Results: Ten studies with 797 patients were identified. According to pooled REs analysis, overall response rate was 19%, most frequent, all-grade toxicities were fat…

Male0301 basic medicineOncologyUrologic Neoplasmsmedicine.medical_specialtyVomitingNauseamedicine.medical_treatmentMEDLINEPlatinum CompoundsNeutropeniaVinblastine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineNeoplasm MetastasisFatigueAgedChemotherapyVinfluninebusiness.industryNauseaHematologyMiddle Agedmedicine.diseaseEuropeClinical trialTreatment Outcome030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisMeta-analysisVomitingFemalemedicine.symptombusinessConstipationCritical Reviews in Oncology/Hematology
researchProduct

Relations of Sex to Diagnosis and Outcomes in Acute Coronary Syndrome

2018

Background The atypical presentation of women with acute coronary syndrome ( ACS ) has been related to delayed diagnosis and treatment, which may explain worse outcome compared with men. Methods and Results We analyzed pooled data of 2520 patients of 2 prospective cohorts in terms of differences in presentation and management of women and men suggestive of ACS . Using logistic regression, we established 2 diagnostic models and tested their diagnostic performance in both sexes separately. Sex‐specific differences in management of patients with ACS were ascertained and a 2‐year follow‐up was performed. Women were older than men (median 67 versus 61 years, P =0.001), had more often dyspnea (2…

MaleAcute coronary syndromemedicine.medical_specialtyTime FactorsdiagnosisNauseaCoronary Artery Disease030204 cardiovascular system & hematologyLogistic regressionChest painRisk Assessment03 medical and health sciencesSex Factors0302 clinical medicinePredictive Value of TestsRisk FactorsGermanyInternal medicinemedicineCoronary Heart DiseaseHumansMedical history030212 general & internal medicineAcute Coronary SyndromeHealthcare DisparitiesOriginal ResearchAgedtroponinbusiness.industryIncidencesex‐specificReproducibility of ResultsHealth Status DisparitiesMiddle Agedmedicine.disease3. Good healthClinical trialTreatment OutcomeoutcomeVomitingFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessAcute Coronary SyndromesDyslipidemiaJournal of the American Heart Association
researchProduct

High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck

1992

A group of 60 patients with advanced head/neck cancer were treated with high-dose folinic acid (500 mg/m-2/week-1) plus 5-fluorouracil (400 mg/m-2/week-1 on day 1, and cisplatin (20 mg/m-2/week-1) 24 h after folinic acid infusion was completed. Out of 55 evaluable patients, 10 patients (18%) experienced a complete response with a mean duration of 11.4+ months, 25 patients had a partial response (45%) of 6.7+ months, 6 patients (11%) showed a stabilization of 4.8+ months, and 14 (25%) progressed. The overall response rate was 63.6% (95% confidence limits 56.5%-69.5%). Patients pretreated with radiotherapy had a 67% overall response rate, while those pretreated with chemotherapy showed a 54% …

MaleCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentCystadenocarcinomaLeucovorinAdenocarcinomaGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisChemotherapyLeukopeniabusiness.industryCarcinomaCancerGeneral MedicineMiddle Agedmedicine.diseaseRadiation therapyOncologyHead and Neck NeoplasmsFluorouracilAnesthesiaCarcinoma Squamous CellVomitingFemaleFluorouracilCisplatinmedicine.symptombusinessmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Symptom Expression in Patients with Advanced Cancer Admitted to an Acute Supportive/Palliative Care Unit With and Without Delirium

2018

Abstract Aim The aim of this study was to investigate the relationship between delirium and symptom expression in patients with advanced cancer admitted to an acute supportive/palliative care unit (ASPCU). Methods A consecutive sample of patients with advanced cancer who were admitted to an ASPCU was prospectively assessed for a period of 10 months. The Edmonton Symptom Assessment Scale (ESAS) and the MDAS (Memorial Delirium Assessment Scale) were measured at admission (T0) and after 7 days of palliative care (T7). Results Two hundred forty-six patients had complete data regarding MDAS measurements, at either T0 and T7. Of these, 75 (30.5%) and 63 patients (25.6%) had delirium at T0 and aft…

MaleCancer Researchmedicine.medical_specialtyWeaknessPalliative careNauseaNeuropsychological TestsSeverity of Illness Indexbehavioral disciplines and activities03 medical and health sciencesCognition0302 clinical medicineAdvanced cancerNeoplasmsInternal medicinemental disordersHumansMedicineProspective Studies030212 general & internal medicineKarnofsky Performance StatusDepression (differential diagnoses)Edmonton Symptom Assessment ScaleAgedNeoplasm StagingPain MeasurementDepressionbusiness.industryPalliative CareDeliriumCancerMemorial Delirium Assessment ScaleCancer PainMiddle Agedmedicine.diseaseAdvanced cancernervous system diseasesHospitalizationTreatment OutcomeOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisBehavior Rating ScaleAnxietyDeliriumFemaleSymptom Assessmentmedicine.symptombusinessThe Oncologist
researchProduct